A new marker in Sepsis management
Sepsis is the body’s systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure and death. There are over 18 million cases of severe sepsis worldwide each year with an estimated annual cost of treating sepsis in the US alone of $17 billion (€13 billion). Early and accurate diagnosis of severe sepsis is essential for the survival of the patient – for every hour that proper treatment is delayed, the mortality associated with severe sepsis increases by 7.5%. Heparin Binding Protein (HBP) is a new biomarker that has demonstrated utility in identifying patients at risk of developing severe sepsis. HBP is an inflammatory mediator secreted by neutrophil white blood cells in response to an infection. A recent study demonstrated that an elevated plasma HBP level was a good indicator of severe sepsis (with or without septic shock) with a sensitivity of 87.1% and a specificity of 95.1%. The new CE-marked HBP assay from Axis-Shield is a simple ELISA assay for the measurement of HBP in plasma samples.
Supplier: Axis-Shield Diagnostics
Website:
